Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Stockholm - Free Realtime Quote SEK

Biosergen AB (BIOSGN.ST)

Compare
0.3400
-0.0190
(-5.29%)
As of 10:21:55 AM GMT+2. Market Open.
Loading Chart for BIOSGN.ST
  • Previous Close 0.3590
  • Open 0.3310
  • Bid 0.3310 x --
  • Ask 0.3400 x --
  • Day's Range 0.3310 - 0.3400
  • 52 Week Range 0.2700 - 1.1400
  • Volume 24,305
  • Avg. Volume 295,590
  • Market Cap (intraday) 79.84M
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1500
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1.50

Biosergen AB, a biotech company, develops antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of fungal infections. The company was founded in 2004 and is based in Solna, Sweden.

biosergen.net

2

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIOSGN.ST

View More

Performance Overview: BIOSGN.ST

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

BIOSGN.ST
35.85%
OMX Stockholm 30 Index (^OMX)
2.95%

1-Year Return

BIOSGN.ST
13.71%
OMX Stockholm 30 Index (^OMX)
4.13%

3-Year Return

BIOSGN.ST
92.75%
OMX Stockholm 30 Index (^OMX)
13.69%

5-Year Return

BIOSGN.ST
95.22%
OMX Stockholm 30 Index (^OMX)
71.56%

Compare To: BIOSGN.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIOSGN.ST

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    84.30M

  • Enterprise Value

    33.69M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.72

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -38.69%

  • Return on Equity (ttm)

    -73.32%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -18.79M

  • Diluted EPS (ttm)

    -0.1500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    50.61M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -10.04M

Research Analysis: BIOSGN.ST

View More

Company Insights: BIOSGN.ST

Research Reports: BIOSGN.ST

View More

People Also Watch